8-K: Aptose Biosciences Secures Additional Funding, Reports Positive Tuspetinib Triplet Therapy Data for AML

Aptose Biosciences Inc. announced receipt of a US$2.0 million advance from Hanmi Pharmaceutical, bringing total advances to US$4.5 million under an US$8.5 million loan agreement, to further develop its tuspetinib-based triplet therapy for acute myeloid leukemia.

Summary

• Aptose Biosciences Inc. received an additional advance of US$2.0 million from Hanmi Pharmaceutical Co. Ltd. on July 15, 2025.
• This advance is part of a US$8.5 million loan facility agreement with Hanmi, initially announced on June 20, 2025.
• To date, Aptose has received an aggregate of US$4.5 million under this Loan Agreement.
• The funds will be used to continue the clinical development of tuspetinib (TUS) in a triplet therapy for newly diagnosed acute myeloid leukemia (AML).
• The TUS+VEN+AZA triplet therapy continues to demonstrate exciting antileukemic activity and safety across genetically diverse populations of newly diagnosed AML patients, including TP53-mutated AML and wildtype AML.
• Tuspetinib is a convenient once-daily oral agent that inhibits SYK, mutated and wild type forms of FLT3, mutated KIT, JAK1/2, and RSK2 kinases, while maintaining a favorable safety profile.
• The ongoing TUSCANY triplet Phase 1/2 study is designed to test various doses and schedules of TUS in combination with standard dosing of azacitidine and venetoclax in newly diagnosed AML patients ineligible for induction chemotherapy.
• Early data from the first two dose cohorts of the TUSCANY study, reported at the European Hematology Association Congress in June, demonstrated safety, complete responses (CRs), and minimal residual disease (MRD) negativity across patients with diverse mutations.

Sentiment

Score: 8

Explanation: The document reports positive early clinical data for a key drug candidate in an area of high unmet medical need, coupled with the successful receipt of a significant loan advance that extends funding for the study. These factors represent strong progress and de-risking for a clinical-stage biotechnology company.

Positives

• Received an additional US$2.0 million advance from Hanmi Pharmaceutical, bringing total advances to US$4.5 million, which extends the ability to fund the important tuspetinib study.
• Tuspetinib in triplet therapy (TUS+VEN+AZA) continues to demonstrate exciting antileukemic activity and safety.
• The therapy shows activity across genetically diverse populations of newly diagnosed AML patients, including TP53-mutated AML and wildtype AML, which represent large populations with few current treatment options.
• Tuspetinib is a convenient once-daily oral agent with a favorable safety profile, avoiding typical toxicity concerns observed with other agents.
• Early data from the TUSCANY triplet Phase 1/2 study demonstrated safety, complete responses (CRs), and minimal residual disease (MRD) negativity across patients with diverse mutations.

Risks

• Ability to negotiate a collaboration agreement to jointly develop tuspetinib with Hanmi.
• Ability to remain compliant with Nasdaq listing requirements.
• Forward-looking statements are subject to significant business, economic, competitive, political, and social uncertainties and contingencies.
• Actual results, performance, or achievements could be materially different from any future results, performance, or achievements described in this press release due to various factors.

Future Outlook

Aptose Biosciences intends to continue the development of tuspetinib, particularly as a frontline triplet therapy for newly diagnosed AML. The ongoing TUSCANY triplet Phase 1/2 study will continue to test various doses and schedules of tuspetinib in combination with standard dosing of azacitidine and venetoclax.

Management Comments

• "Tuspetinib in combination with venetoclax and azacitidine (the TUS+VEN+AZA triplet) continues to demonstrate exciting antileukemic activity and safety across genetically diverse populations of newly diagnosed AML patients including TP53-mutated AML and wildtype AML, representing large AML populations for which there are few treatment options." William G. Rice, Ph.D., Chairman, President and Chief Executive Officer of Aptose.
• "We are very grateful to Hanmi for its continued support to help advance tuspetinib clinical development and further extend Aptose's ability to fund this important study." William G. Rice, Ph.D., Chairman, President and Chief Executive Officer of Aptose.

Industry Context

The announcement highlights Aptose's focus on addressing unmet medical needs in oncology, specifically in acute myeloid leukemia (AML). The emphasis on TP53-mutated and wildtype AML populations underscores the significant need for new treatment options in these large patient groups where current therapies are limited. Aptose's precision medicine approach with tuspetinib, designed for single-agent efficacy and enhanced combination therapy without overlapping toxicities, positions it as a potential advancement in the competitive hematology oncology landscape.

Comparison to Industry Standards

• Tuspetinib is targeting large AML populations, including TP53-mutated AML and wildtype AML, for which there are stated to be "few treatment options," indicating a high unmet medical need compared to areas with established, effective therapies.
• Tuspetinib is noted to maintain a "favorable safety profile by avoiding typical toxicity concerns observed with other agents," suggesting a potential advantage in tolerability compared to existing or developing AML treatments.

Stakeholder Impact

• Shareholders: Positive impact due to extended funding, positive clinical data, and progress in drug development, potentially increasing company value.
• Patients: Potential for a new, effective, and well-tolerated treatment option for AML, especially for underserved populations like TP53-mutated and wildtype AML.
• Employees: Continued employment and progress on a key pipeline asset.
• Hanmi Pharmaceutical: Strengthened partnership and potential future returns from their investment/collaboration.

Next Steps

• Continue development of tuspetinib in triplet therapy for AML.
• Continue the ongoing TUSCANY triplet Phase 1/2 study to test various doses and schedules of TUS in combination with standard dosing of azacitidine and venetoclax.

Key Dates

Recommendation

Keywords

Aptose Biosciences, Tuspetinib, AML, Acute Myeloid Leukemia, Oncology, Clinical Trial, Phase 1/2, TUSCANY study, Hanmi Pharmaceutical, Loan Agreement, Precision Oncology, Hematology, SYK inhibitor, FLT3 inhibitor, Venetoclax, Azacitidine, TP53-mutated AML, Wildtype AML, MRD negativity, Complete Response